A Study to Learn How Well the Treatment Combination of Finerenone and Empagliflozin Works and How Safe it is Compared to Each Treatment Alone in Adult Participants With Long-term Kidney Disease (Chronic Kidney Disease) and Type 2 Diabetes
- Conditions
- Type 2 Diabetes MellitusChronic Kidney Disease
- Interventions
- Registration Number
- NCT05254002
- Lead Sponsor
- Bayer
- Brief Summary
Finerenone works by blocking a group of proteins, called mineralocorticoid receptor. An increased stimulation of mineralocorticoid receptor is known to trigger injury and inflammation in the kidney and is therefore thought to play a role in CKD.
Empagliflozin lowers blood sugar levels by increasing the excretion of glucose from the blood into the urine.
In this study, the researchers want to learn how well the combination of finerenone and empagliflozin helps to slow down the worsening of the participants' kidney function compared to either treatment alone. For this, the level of protein in the urine will be measured. The investigators also want to know how safe the combination is compared to either treatment alone.
Depending on the treatment group, the participants will either take the combination of finerenone and empagliflozin, or finerenone together with a placebo, or empagliflozin together with a placebo, once a day as tablets by mouth. A placebo looks like a treatment but does not have any medicine in it. Importantly, the participants will also continue to take their other current medicine for CKD and T2D.
The participants will be in the study for up to 7.5 months and will take the study treatments for 6 months. During the study, participants will visit the study site 7 times.
The study team will:
* collect blood and urine samples
* check the participants' vital signs
* do a physical examination including height and weight
* check the participants' heart health by using an electrocardiogram (ECG)
* monitor the participants' blood pressure
* ask the participants questions about how they are feeling and what adverse events they may be having An adverse event is any problem that happens during the trial. Doctors keep track of all events that happen in trials, even if they do not think the events might be related to the study treatments.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 1664
-
Participant with a clinical diagnosis of chronic kidney disease (CKD) and the following:
- In Part A: eGFR 40-90 ml/min/1.73m^2 (with no more than 20% having an eGFR >75 ml/min/1.73m^2) using Chronic Kidney Disease Epidemiology Collaboration (CKD EPI) formula at screening visit and at least one historical value of eGFR <60 mL/min/1.73 m^2 within 3 months or have a registered diagnosis of CKD.
- In Part B: eGFR 30-90 ml/min/1.73m^2 (with no more than 20% having an eGFR >75 ml/min/1.73m^2) using CKD-EPI formula at screening visit and at least one historical value of eGFR <60 mL/min/1.73 m^2 within 3 months or have a registered diagnostic of CKD.
- 100 ≤UACR <5000 mg/g at screening visit (mean value from 3 morning void samples) and documentation of albuminuria/proteinuria (quantitative or semi-quantitative measurement) in the participant's medical records at least 3 months prior to screening
-
Participant with type 2 diabetes (T2D) as defined by the American Diabetes Association (ADA 2021), with glycated hemoglobin (HbA1c) at screening <11%.
-
Participant treated with the clinically maximum tolerated dose, as per investigator judgment, of angiotensin-converting enzyme inhibitor (ACEi) or angiotensin receptor blocker (ARB), but not both, for more than 1 month at screening visit.
- Participants with type 1 diabetes (T1D).
- Participant with hepatic insufficiency classified as Child-Pugh C.
- Participant with blood pressure at Day 1 visit (Visit 2) higher than 160 systolic blood pressure (SBP) or 100 diastolic blood pressure (DBP) or SBP lower than 90 mmHg.
- Participant currently treated with a sodium/glucose cotransporter-2 inhibitor (SGLT2i) or SGLT-1/2i or who received a SGLT2i or SGLT-1/2i which cannot be discontinued at least 8 weeks prior to the screening visit and during study intervention treatment.
- Participant treated with another mineralocorticoid receptor antagonist (MRA) (e.g., eplerenone, esaxerenone, spironolactone, canrenone), a renin inhibitor, potassium supplements, a potassium sparing diuretic (e.g., amiloride, triamterene), a potassium binder agent, or angiotensin receptor-neprilysin inhibitor (ARNI) which cannot be discontinued at least 8 weeks prior to the screening visit and during study intervention treatment.
- Participants currently treated or who were treated with Finerenone (Kerendia©) within 8 weeks prior to the screening visit.
- Participant with serum/plasma potassium (K+) above 4.8 mmol/L at screening visit (central laboratory value).
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description Finerenone and Empagliflozin Finerenone (BAY94-8862 ) 20 mg Participants will take Finerenone (10 or 20 mg once daily \[OD\]) and Empagliflozin (10 mg OD) for up to 180 days. Finerenone and Empagliflozin placebo Empagliflozin Placebo Participants will take Finerenone (10 or 20 mg OD) and matching placebo to Empagliflozin (OD) for up to 180 days. Finerenone and Empagliflozin placebo Finerenone (BAY94-8862 ) 20 mg Participants will take Finerenone (10 or 20 mg OD) and matching placebo to Empagliflozin (OD) for up to 180 days. Finerenone and Empagliflozin placebo Finerenone (BAY94-8862 ) 10 mg Participants will take Finerenone (10 or 20 mg OD) and matching placebo to Empagliflozin (OD) for up to 180 days. Empagliflozin and Finerenone placebo Finerenone Placebo Participants will take Empagliflozin (10 mg OD) and matching placebo to Finerenone (OD). for up to 180 days. Finerenone and Empagliflozin Finerenone (BAY94-8862 ) 10 mg Participants will take Finerenone (10 or 20 mg once daily \[OD\]) and Empagliflozin (10 mg OD) for up to 180 days. Finerenone and Empagliflozin Empagliflozin Participants will take Finerenone (10 or 20 mg once daily \[OD\]) and Empagliflozin (10 mg OD) for up to 180 days. Empagliflozin and Finerenone placebo Empagliflozin Participants will take Empagliflozin (10 mg OD) and matching placebo to Finerenone (OD). for up to 180 days.
- Primary Outcome Measures
Name Time Method Mean ratio of change from baseline to Day 180 in UACR for the combination therapy group, to finerenone alone Up to 180 days Mean ratio of change from baseline to Day 180 in UACR for the combination therapy group, to empagliflozin alone Upto 180 days Relative change from baseline in UACR at 180 days in combination therapy group versus empagliflozin alone Up to 180 days Urinary albumin to-creatinine ratio (UACR)
Relative change from baseline in UACR at 180 days in combination therapy group versus finerenone alone Up to 180 days
- Secondary Outcome Measures
Name Time Method Total number of ketoacidosis events Up to 180 days Proportion of participants with symptomatic hypotension events Up to 180 days Proportion of participants with necrotizing fasciitis of the perineum events Up to 180 days Total number of urosepsis and pyelonephritis events Up to 180 days Proportion of participants with severe hypoglycemia events Up to 180 days Severe hypoglycemia is defined as glucose level of \<3.0 mmol/L (\<54 mg/dL).
Relative change in UACR between end of treatment visit (Day 180) and 30 days after end of treatment visit (Day 210) Up to 210 days Total number of events of severe hypoglycemia events Up to 180 days Relative change in UACR between 30 days after end of treatment visit (Day 210) and baseline (Day 1) Up to 210 days Relative change in UACR category (>30%, >40%, >50%) at 180 days Up to 180 days Ratio of change from baseline in eGFR at 30 days Up to 30 days estimated glomerular filtration rate (eGRF)
eGFR decline greater than 30% at 30 days from baseline Up to 30 days Proportion of participants with of acute kidney injury (AKI) events Up to 180 days AKI is defined as any of the following:
* An increase in serum creatinine by greater than or equal to 0.3 mg/dL within 48 hours; or
* An increase in serum creatinine by greater than or equal to 1.5 times baseline, which is known or presumed to have occurred within the prior 7 days; or
* A urine volume less than 0.5 ml/kg/h for 6 hoursTotal number of symptomatic hypotension events Up to 180 days Proportion of participants with genital mycotic events Up to 180 days Ratio of change in eGFR at 180 days and 210 days from Day 30 Up to 210 days Total number of AKI events Up to 180 days Proportion of participants with hyperkalemia events (moderate hyperkalemia [5.5 <K+ ≤6.0 mmol/L], severe hyperkalemia [K+ >6.0 mmol/L]) Up to 180 days serum/plasma potassium (k+)
Total number of hyperkalemia events (moderate hyperkalemia [5.5 <K+ ≤6.0 mmol/L], severe hyperkalemia [K+ >6.0 mmol/L]) Up to 180 days Change from baseline in K+ Up to 180 days Proportion of participants with ketoacidosis events Up to 180 days Total number of necrotizing fasciitis of the perineum events Up to 180 days Proportion of participants with urosepsis and pyelonephritis events Up to 180 days Total number of genital mycotic events Up to 180 days
Trial Locations
- Locations (181)
Recherche GCP Research
🇨🇦Montreal, Quebec, Canada
Southwest Kidney Institute, PLC
🇺🇸Surprise, Arizona, United States
Academic Medical Research Institute
🇺🇸Los Angeles, California, United States
Northridge Hospital
🇺🇸Northridge, California, United States
Olive View - UCLA Medical Center
🇺🇸Sylmar, California, United States
Touro University California
🇺🇸Vallejo, California, United States
Chase Medical Research, LLC
🇺🇸Waterbury, Connecticut, United States
Florida Kidney Physicians - Delray Beach Nephrology
🇺🇸Delray Beach, Florida, United States
West Orange Endocrinology & Clinical Research
🇺🇸Ocoee, Florida, United States
Innovative Research Institute
🇺🇸Port Charlotte, Florida, United States
Metabolic Research Institute, Inc.
🇺🇸West Palm Beach, Florida, United States
Grady Memorial Hospital - Endocrinology
🇺🇸Atlanta, Georgia, United States
Southeast Kidney Associates
🇺🇸East Point, Georgia, United States
Velocity Clinical Research - Savannah
🇺🇸Savannah, Georgia, United States
Versailles Family Medicine
🇺🇸Versailles, Kentucky, United States
Nola Care Clinical Research
🇺🇸Metairie, Louisiana, United States
Omega Clinical Research Center
🇺🇸Metairie, Louisiana, United States
South Shore Nephrology
🇺🇸Plymouth, Massachusetts, United States
Lake Michigan Nephrology
🇺🇸Saint Joseph, Michigan, United States
Clinical Research Consultants
🇺🇸Kansas City, Missouri, United States
Kansas City VA Medical Center - Endocrinology
🇺🇸Kansas City, Missouri, United States
Washington University School of Medicine in St. Louis
🇺🇸Saint Louis, Missouri, United States
St. Louis Heart & Vascular, PC
🇺🇸Saint Louis, Missouri, United States
Somnos Clinical Research
🇺🇸Lincoln, Nebraska, United States
Meridian Clinical Research- Norfolk
🇺🇸Norfolk, Nebraska, United States
Healor Primary Care / CCT Research
🇺🇸Las Vegas, Nevada, United States
Santa Rosa Medical Centers of Nevada / CCT Research
🇺🇸Las Vegas, Nevada, United States
Circuit Clinical/Crystal Run
🇺🇸Middletown, New York, United States
Randolph Medical Associates
🇺🇸Asheboro, North Carolina, United States
University of North Carolina Kidney Center
🇺🇸Chapel Hill, North Carolina, United States
Eastern Nephrology Associates - Greenville West
🇺🇸Greenville, North Carolina, United States
Blue Sky, MD/ Lamond Family Medicine
🇺🇸Hendersonville, North Carolina, United States
Eastern Nephrology Associates - Kinston
🇺🇸Kinston, North Carolina, United States
Velocity Clinical Research, Cincinnati
🇺🇸Cincinnati, Ohio, United States
Oakland Medical Center
🇺🇸Dakota Dunes, South Dakota, United States
Dunes Clinical Research LLC
🇺🇸Dakota Dunes, South Dakota, United States
DarSalud Care / LifeDOC Research
🇺🇸Memphis, Tennessee, United States
University of Tennessee Health Science Center
🇺🇸Memphis, Tennessee, United States
Office of Osvaldo A. Brusco, MD
🇺🇸Corpus Christi, Texas, United States
Thyroid, Endocrinology, and Diabetes (TED) PA
🇺🇸Dallas, Texas, United States
DaVita Clinical Research- El Paso
🇺🇸El Paso, Texas, United States
Global Kidney Center
🇺🇸Houston, Texas, United States
Victorium Clinical Research
🇺🇸Houston, Texas, United States
North Texas Kidney Disease Associates, PLLC
🇺🇸Lewisville, Texas, United States
Biopharma Informatic - McAllen, TX
🇺🇸McAllen, Texas, United States
Clinical Advancement Center, PLLC
🇺🇸San Antonio, Texas, United States
University of Texas Health Science Center
🇺🇸San Antonio, Texas, United States
Olympus Family Medicine
🇺🇸Salt Lake City, Utah, United States
Salem VA Medical Center - Endocrinology
🇺🇸Salem, Virginia, United States
MultiCare Rockwood Clinic Diabetes & Endocrinology Center
🇺🇸Spokane, Washington, United States
CHU de Charleroi Hôpital civil
🇧🇪Lodelinsart, Hainaut, Belgium
Onze-Lieve-Vrouwziekenhuis (OLVZ) - Campus Aalst
🇧🇪Aalst, Oost-vlaanderen, Belgium
AZ St-Lucas Campus St-Lucas
🇧🇪Gent, Belgium
UZ Gent
🇧🇪Gent, Belgium
Regionaal ZH Jan Yperman Campus Mariaziekenhuis
🇧🇪Ieper, Belgium
AZ Groeninge Campus Kennedylaan
🇧🇪Kortrijk, Belgium
UZ Leuven Gasthuisberg
🇧🇪Leuven, Belgium
AZ Delta
🇧🇪Roeselare, Belgium
LMC Manna Research - Calgary
🇨🇦Calgary, Alberta, Canada
Hamilton Medical Research Group
🇨🇦Hamilton, Ontario, Canada
William Osler Health centre, Sakuara Medical
🇨🇦Mississauga, Ontario, Canada
Bluewater Clinical Research Group
🇨🇦Sarnia, Ontario, Canada
Sameh Fikry Professional Corporation
🇨🇦Waterloo, Ontario, Canada
Clinical Research Solutions, Inc.
🇨🇦Waterloo, Ontario, Canada
Centre Hospitalier de l'Université de Montréal (CHUM)
🇨🇦Montreal, Quebec, Canada
LMC Clinical Research Inc. Montreal
🇨🇦Ville Saint-Laurent, Quebec, Canada
Hospital of South West Jutland | Department of Endocrinology Research
🇩🇰Esbjerg, Denmark
Steno Diabetes Center Copenhagen | Herlev - Clinical and Translational Research Department
🇩🇰Herlev, Denmark
Region Midtjylland | Regionshospitalet Godstrup - Nephrology Department
🇩🇰Herning, Denmark
Bispebjerg Hospital - Hjerteafdeling
🇩🇰København, Denmark
Hôpital François Mitterrand - Dijon
🇫🇷Dijon, France
Center Hospitalier Michallon - Grenoble
🇫🇷Grenoble Cedex 9, France
Hôpital Edouard Herriot - Lyon Cedex
🇫🇷Lyon Cedex, France
Many Locations
🇨🇳Multiple Locations, Taiwan
Hopital Carémeau - Nîmes
🇫🇷Nîmes, France
Hôpital Saint Joseph
🇫🇷Paris, France
St. Josefskrankenhaus
🇩🇪Heidelberg, Baden-Württemberg, Germany
ClinPhenomics GmbH&Co. KG
🇩🇪Frankfurt, Hessen, Germany
Diabetologische Schwerpunkt Praxis Dortmund
🇩🇪Dortmund, Nordrhein-Westfalen, Germany
Zentrum für Diabetologie und Ernährungsmedizin
🇩🇪Ludwigshafen, Rheinland-Pfalz, Germany
Cardiologicum Pirna / Dresden-Seidnitz
🇩🇪Pirna, Sachsen, Germany
Friedrich-Schiller-Uni. Jena
🇩🇪Jena, Thüringen, Germany
Charité Campus Benjamin Franklin (CBF)
🇩🇪Berlin, Germany
Diabetes Zentrum Wandsbek
🇩🇪Hamburg, Germany
King George Hospital
🇮🇳Visakhapatnam, AP, India
All India Institute of Medical Sciences
🇮🇳Bhubaneswar, Delhi, India
Indraprastha Apollo Hospital
🇮🇳New Delhi, Delhi, India
Mavani Dialysis & Kidney Center
🇮🇳Ahmedabad, GJ, India
K.L.E.S. Dr. Prabhakar Kore Hospital & Medical Research Centre
🇮🇳Belgaum, Karnataka, India
Manipal Hospital
🇮🇳Mysore, Karnataka, India
Asian Kidney Hospital and Medical Centre
🇮🇳Nagapur, MH, India
Eternal Heart Care Centre (EHCC) and Research Institute
🇮🇳Jaipur, Rajasthan, India
G.S.V.M. Medical College
🇮🇳Kanpur, Uttar Pradesh, India
Institute of Post-Graduate Medical Education and Research
🇮🇳Kolkata, West Bengal, India
Dr. Bantwal's Clinic
🇮🇳Bengaluru, India
Bangalore Medical College & Research Institute
🇮🇳Bengaluru, India
Government Kilpauk Medical College Hospital
🇮🇳Chennai, India
Sriram Chandra Bhanj Medical College & Hospital
🇮🇳Cuttack, India
Nizam's Institute of Medical Sciences (NIMS)
🇮🇳Hyderabad, India
Sawami Man Singh (SMS) Medical College & Attached Hospitals
🇮🇳Jaipur, India
Government Medical College
🇮🇳Kozhikode, India
Vinaya Hospital and Research Centre (A Unit of KIMS)
🇮🇳Mangalore, India
Seth Gordhandas Sunderdas Medical College (GSMC) - King Edward Memorial (KEM) Hospital
🇮🇳Mumbai, India
Government Medical College and Hospital (GMCH) Nagpur
🇮🇳Nagpur, India
Max Super Speciality Hospital (MSSH) - Saket
🇮🇳New Delhi, India
Grant Medical Foundation - Ruby Hall Clinic (RHC)
🇮🇳Pune, India
Lifepoint Multispecialty Hospital
🇮🇳Pune, India
Krishna Institute Of Medical Science
🇮🇳Secunderabad, India
Osmania General Hospital
🇮🇳Telangana, India
Vedanta Kidney Care
🇮🇳Vadodara, India
HaEmek Medical Center | Internal Medicine C Department - Research Unit
🇮🇱Afula, Israel
Barzilai Medical Center | Department of Nephrology and Hypertension
🇮🇱Ashkelon, Israel
Clalit Health | Soroka Medical Center - Internal Medicine Department
🇮🇱Beer Sheva, Israel
Edith Wolfson Medical Center | Internal Medicine Department
🇮🇱Holon, Israel
Hadassah University Medical Center (HUMC)
🇮🇱Jerusalem, Israel
Health Corporation of Galilee Medical Center
🇮🇱Nahariya, Israel
Rabin Medical Center | Beilinson Hospital - Internal Medicine C Department
🇮🇱Petach Tikva, Israel
Health Corporation of the Ziv Medical Center (R.A.)
🇮🇱Zefat, Israel
Azienda Ospedaliero Universitaria Parma - SC Nefrologia
🇮🇹Parma, Emilia-Romagna, Italy
ASL 4 Chiavarese
🇮🇹Chiavari, Liguria, Italy
Azienda Socio Sanitaria Territoriale Papa Giovanni XXIII - Malattie Endocrine e Diabetologia
🇮🇹Bergamo, Lombardia, Italy
Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico - Endocrinologia
🇮🇹Milano, Lombardia, Italy
Ospedale San Raffaele s.r.l. - Medicina Generale Indirizzo Diabetologico ed Endocrino-Metabolico
🇮🇹Milano, Lombardia, Italy
Azienda Socio Sanitaria Territoriale Santi Paolo e Carlo_Ospedale S. Paolo - Gestione integrata della malattia Diabetica
🇮🇹Milano, Lombardia, Italy
Azienda Socio Sanitaria Territoriale Rhodense
🇮🇹Rho, Lombardia, Italy
Azienda Ospedaliero-Universitaria San Luigi Gonzaga - Malattie Metaboliche Diabetologia
🇮🇹Orbassano, Piemonte, Italy
Casa Sollievo della Sofferenza - Endocrinologia
🇮🇹San Giovanni Rotondo, Puglia, Italy
Azienda Socio Sanitaria Locale N 2 Della Gallura - Diabetologia
🇮🇹Olbia, Sardegna, Italy
Azienda Ospedaliero Universitaria Pisana_Cisanello - Malattie Metaboliche e Diabetologia
🇮🇹Pisa, Toscana, Italy
Azienda Ospedaliera Universitaria Integrata Verona_Borgo Roma - Endocrinologia, Diabetologia e Malattie del Metabolismo
🇮🇹Verona, Veneto, Italy
Università degli Studi "G. D'Annunzio" di Chieti - Endocrinologia
🇮🇹Chieti, Italy
Saiseikai Matsuyama Hospital
🇯🇵Matsuyama, Ehime, Japan
Fukuoka University Chikushi Hospital
🇯🇵Chikushino, Fukuoka, Japan
Kokura Memorial Hospital
🇯🇵Kitakyushu, Fukuoka, Japan
Hirohata Naika Clinic
🇯🇵Kitakyushu, Fukuoka, Japan
Jiyugaoka Yamada Internal Medicine Clinic
🇯🇵Obihiro, Hokkaido, Japan
Naka Kinen Clinic
🇯🇵Naka-shi, Ibaraki, Japan
Public Central Hospital of Matto Ishikawa | Clinical Trial Management Office
🇯🇵Hakusan, Ishikawa, Japan
Fukui-ken Saiseikai Hospital
🇯🇵Fukui, Japan
Social Medical Corporation the Chiyukai foundation Fukuoka Wajiro Hospital
🇯🇵Fukuoka, Japan
Japanese Red Cross Kumamoto Hospital
🇯🇵Kumamoto, Japan
Medical Corporation Taifukukai, Osaka Nishiumeda Clinic
🇯🇵Osaka, Japan
Osaka General Medical Center
🇯🇵Osaka, Japan
Soon Chun Hyang University Cheonan Hospital
🇰🇷Cheonan, Chungcheongnamdo, Korea, Republic of
Yonsei University Wonju Christian Hospital
🇰🇷Wonju, Gang''weondo, Korea, Republic of
Hallym University Sacred Heart Hospital
🇰🇷Anyang-si, Gyeonggido, Korea, Republic of
Seoul National University Bundang Hospital
🇰🇷Seongnam-si, Gyeonggido, Korea, Republic of
Hospital Universitario Dr. Peset
🇪🇸Valencia, Spain
Hanyang University Guri Hospital
🇰🇷Guri-si, Gyeonggi, Korea, Republic of
The Catholic University of Korea, Incheon St.Mary's Hospital
🇰🇷Incheon, Incheon Gwang''yeogsi, Korea, Republic of
Severance Hospital, Yonsei University Health System
🇰🇷Seoul, Seoul Teugbyeolsi, Korea, Republic of
Asan Medical Center
🇰🇷Seoul, Seoul Teugbyeolsi, Korea, Republic of
Seoul National University Hospital
🇰🇷Seoul, Seoul Teugbyeolsi, Korea, Republic of
Chung Nam National University Hospital
🇰🇷Daejeon, Korea, Republic of
Korea University Ansan Hospital
🇰🇷Gyeonggi-do, Korea, Republic of
Kyung Hee University Hospital at Gangdong
🇰🇷Seoul, Korea, Republic of
Hallym University Kangnam Sacred Heart Hospital
🇰🇷Seoul, Korea, Republic of
Meander Medisch Centrum
🇳🇱Amersfoort, Netherlands
Onze Lieve Vrouwe Gasthuis
🇳🇱Amsterdam, Netherlands
Gelre Ziekenhuizen
🇳🇱Apeldoorn, Netherlands
Albert Schweitzer Ziekenhuis | Dordwijk - Cardiology Department
🇳🇱Dordrecht, Netherlands
Gerencia de Gestion Integrada A Coruna | Department of Endocrinology and Nutrition
🇪🇸A Coruna, A Coruña, Spain
Complejo Hospitalario Universitario de Ferrol | Hospital Naval - Unidad de Hipertensión Arterial
🇪🇸Ferrol, A Coruña, Spain
Hospital Principe de Asturias
🇪🇸Alcalá de Henares, Madrid, Spain
H. Costa del Sol (Marbella)
🇪🇸Marbella, Malaga, Spain
Hospital Vithas Sevilla | Endocrinology Department
🇪🇸Castilleja de la Cuesta, Sevilla, Spain
Ciutat Sanitaria i Universitaria de la Vall d'Hebron
🇪🇸Barcelona, Spain
Hospital Quironsalud Barcelona | Internal Medicine Department
🇪🇸Barcelona, Spain
Hospital Universitario Virgen de las Nieves | Servicio de Endocrinologia y Nutricion
🇪🇸Granada, Spain
Hospital Clinico San Carlos
🇪🇸Madrid, Spain
Universidad Autonoma de Madrid (UAM) - Facultad de Medicina - Hospital Universitario Fundacion Jimenez Diaz (UAM-FJD)
🇪🇸Madrid, Spain
Hospital Universitario Puerta de Hierro Majadahonda | Clinical Pharmacology Department
🇪🇸Majadahonda, Spain
Hospital Universitario Virgen de la Victoria | Unidad de Investigacion Clinica - Endocrinology Department
🇪🇸Malaga, Spain
Hospital Clínico Universitario de Valencia
🇪🇸Valencia, Spain
Changhua Christian Hospital
🇨🇳Changhua, Taiwan
Chang Gung Memorial Hospital Kaohsiung
🇨🇳Kaohsiung, Taiwan
Far Eastern Memorial Hospital | Nephrology Department
🇨🇳New Taipei City, Taiwan
Taipei Medical University - Shuang Ho Hospital
🇨🇳New Taipei City, Taiwan
China Medical University Hospital
🇨🇳Taichung, Taiwan
Taichung Veterans General Hospital
🇨🇳Taichung, Taiwan
Taipei Veterans General Hospital
🇨🇳Taipei, Taiwan